Benefits of statin therapy within a year after kidney transplantation

Cardiovascular disease remains a leading cause of morbidity and mortality after kidney transplantation (KT). Although statins reduce cardiovascular risk and have renal benefits in the general population, their effects on KT recipients are not well-established. We studied the effects of early statin...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-01, Vol.14 (1), p.2002-9, Article 2002
Main Authors: Yim, Seung Hyuk, Kim, Hyun Jeong, Ro, Han, Ryu, Jung-Hwa, Kim, Myung-Gyu, Park, Jae Berm, Kim, Chan-Duck, Han, Seungyeup, Lee, Sik, Yang, Jaesok, Huh, Kyu Ha, Kim, Myoung Soo, Lee, Juhan
Format: Article
Language:English
Subjects:
631/250/1854/2812
692/699/1585/104/1586
Biopsy
Body mass index
Cardiovascular diseases
Cholesterol
Cholesterol, LDL
Cohort Studies
Diabetes mellitus
Graft rejection
Health risks
Humanities and Social Sciences
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kidney
Kidney Transplantation
Kidney transplants
Morbidity
Mortality
multidisciplinary
Renal function
Science
Science (multidisciplinary)
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease remains a leading cause of morbidity and mortality after kidney transplantation (KT). Although statins reduce cardiovascular risk and have renal benefits in the general population, their effects on KT recipients are not well-established. We studied the effects of early statin use (within 1-year post-transplantation) on long-term outcomes in 714 KT recipients from the Korean cohort study for outcome in patients with KT. Compared with the control group, statin group recipients were significantly older, had a higher body mass index, and had a higher prevalence of diabetes mellitus. During a median follow-up of 85 months, 74 graft losses occurred (54 death-censored graft losses and 20 deaths). Early statin use was independently associated with lower mortality (hazard ratio, 0.280; 95% confidence interval 0.111–0.703) and lower death-censored graft loss (hazard ratio, 0.350; 95% confidence interval 0.198–0.616). Statin therapy significantly reduced low-density lipoprotein cholesterol levels but did not decrease the risk of major adverse cardiovascular events. Biopsy-proven rejection and graft renal function were not significantly different between statin and control groups. Our findings suggest that early statin use is an effective strategy for reducing low-density lipoprotein cholesterol and improving patient and graft survival after KT.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-52513-6